RCUS (Arcus Biosciences, Inc.)
Insider Trading Activity
Every open-market purchase and sale reported by RCUS officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-08-24 | Alexander Azoy | Chief Accounting Officer | MIXED | — | — |
| 2026-07-13 | Juan C. Jaen | President | Sell | — | — |
| 2026-06-24 | Juan C. Jaen | President | Sell | — | — |
| 2026-06-12 | David L. Lacey | Director | A | — | — |
| 2026-06-12 | Carolyn C. Tang | General Counsel | M | — | — |
| 2026-06-12 | Antoni Ribas | Director | A | — | — |
| 2026-06-12 | KATHRYN E FALBERG | Director | A | — | — |
| 2026-06-12 | Patrick Machado | Director | A | — | — |
| 2026-06-12 | Nicole Lambert | Director | A | — | — |
| 2026-06-12 | YASUNORI KANEKO | Director | A | — | — |
| 2026-06-12 | ANDREW J PERLMAN | Director | A | — | — |
| 2026-06-01 | Alexander Azoy | Chief Accounting Officer | Sell | — | — |
| 2026-05-12 | II Robert C. Goeltz | Chief Financial Officer | Sell | — | — |
| 2026-05-12 | Antoni Ribas | Director | G | — | — |
| 2026-01-26 | II Robert C. Goeltz | Chief Financial Officer | A | — | — |
| 2026-01-26 | Richard Markus | Chief Medical Officer | A | — | — |
| 2026-01-26 | Jennifer Jarrett | Chief Operating Officer | A | — | — |
| 2026-01-26 | Carolyn C. Tang | General Counsel | A | — | — |
| 2026-01-26 | Alexander Azoy | Chief Accounting Officer | A | — | — |
| 2026-01-26 | Juan C. Jaen | President | A | — | — |
| 2026-01-26 | TERRY J ROSEN | Chief Executive Officer | A | — | — |
| 2026-01-09 | TERRY J ROSEN | Chief Executive Officer | G | — | — |
| 2026-01-07 | Juan C. Jaen | President | Sell | — | — |
| 2026-01-02 | TERRY J ROSEN | Chief Executive Officer | G | — | — |
| 2026-01-02 | II Robert C. Goeltz | Chief Financial Officer | Sell | — | — |
| 2025-12-18 | Richard Markus | Chief Medical Officer | Sell | — | — |
| 2025-12-18 | Carolyn C. Tang | General Counsel | Sell | — | — |
| 2025-12-18 | II Robert C. Goeltz | Chief Financial Officer | Sell | — | — |
| 2025-12-18 | TERRY J ROSEN | Chief Executive Officer | Sell | — | — |
| 2025-12-18 | Alexander Azoy | Chief Accounting Officer | Sell | — | — |
| 2025-12-18 | Jennifer Jarrett | Chief Operating Officer | Sell | — | — |
| 2025-12-18 | Juan C. Jaen | President | Sell | — | — |
| 2025-12-05 | Juan C. Jaen | President | Sell | — | — |
| 2025-12-01 | Alexander Azoy | Chief Accounting Officer | MIXED | — | — |
| 2025-11-26 | II Robert C. Goeltz | Chief Financial Officer | Sell | — | — |
| 2025-11-19 | Juan C. Jaen | President | Sell | — | — |
| 2025-11-12 | Jennifer Jarrett | Chief Operating Officer | MIXED | — | — |
| 2025-11-03 | Juan C. Jaen | President | Sell | — | — |
| 2025-10-30 | Juan C. Jaen | President | Sell | — | — |
| 2025-10-29 | II Robert C. Goeltz | Chief Financial Officer | Sell | — | — |
| 2025-10-08 | Jennifer Jarrett | Chief Operating Officer | MIXED | — | — |
| 2025-09-30 | Alexander Azoy | Chief Accounting Officer | Sell | — | — |
| 2025-09-05 | Alexander Azoy | Chief Accounting Officer | Sell | — | — |
| 2025-06-12 | Nicole Lambert | Director | A | — | — |
| 2025-06-12 | KATHRYN E FALBERG | Director | A | — | — |
| 2025-06-12 | Patrick Machado | Director | A | — | — |
| 2025-06-12 | Antoni Ribas | Director | A | — | — |
| 2025-06-12 | David L. Lacey | Director | A | — | — |
| 2025-06-12 | YASUNORI KANEKO | Director | A | — | — |
| 2025-06-12 | ANDREW J PERLMAN | Director | A | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| — | 10%+ Owner | 31,424,760 | — |
| — | Chief Executive Officer | 5,670,279 | — |
| — | 10%+ Owner | 3,125,312 | — |
| — | 10%+ Owner | 1,924,474 | — |
| — | 10%+ Owner | 1,767,676 | — |
| — | 10%+ Owner | 1,496,813 | — |
| — | President | 1,200,799 | — |
| — | Director | 530,750 | — |
| — | Chief Operating Officer | 224,024 | — |
| — | General Counsel | 184,607 | — |
| — | Director | 176,406 | — |
| — | Chief Medical Officer | 89,647 | — |
| — | Chief Medical Officer | 87,518 | — |
| — | Chief Financial Officer | 84,161 | — |
| — | Director | 76,652 | — |
| — | Director | 52,853 | — |
| — | Director | 48,325 | — |
| — | Director | 44,300 | — |
| — | Director | 43,000 | — |
| — | Chief Accounting Officer | 39,581 | — |
| — | Chief Medical Officer | 24,741 | — |
| — | See Remarks | 10,000 | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the RCUS quote page; the site-wide leaderboard is on the insider transactions hub.